We aim to highlight a diagnostic approach toward a new clinical entity of de Novo AML with BCR/ABL1 fusion gene described by WHO in 2016 from CML with BCR/ABL1 gene, which can be challenging in some clinical scenarios. This evidence concerns the gene ABL1 and acute myeloid leukemia.